<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830440</url>
  </required_header>
  <id_info>
    <org_study_id>06-4</org_study_id>
    <nct_id>NCT00830440</nct_id>
  </id_info>
  <brief_title>A Multicenter Study for Pre-Surgical Weight Loss</brief_title>
  <official_title>A Multi-Center, Pilot Efficacy Study of the GI Sleeveâ„¢ for Pre-Surgical Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Dynamics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier
      device compared to a diet control in patients who require weight loss prior to their
      Bariatric surgery.

      It is a randomized, prospective controlled, open label, pilot study of 40 patients. Thiry
      patients will receive an implant of the EndoBarrier device and the other 10 patients will
      receive the principle investigator's standard of care diet program. All patients will be
      treated for 12 weeks with the exception of the last 10 device patients who will continue to
      24 weeks if the principle investigator determines that it is safe and in their best interest
      to continue.

      The primary efficacy endpoint is:

        -  Assessment of the difference in % excess weight loss between the 2 groups

      Secondary endpoints are:

        -  Resolution or Improvement in type II Diabetic status as defined as:

        -  Resolution = patient is off their diabetes medication and has normal diabetic blood
           parameters (fasting glucose)

        -  Improvement = normalizing diabetic blood parameters (fasting glucose) and/or a reduction
           in dosing or frequency of their diabetic medication

        -  The percent of patients who achieve at least a 10% excess weight loss will be calculated
           as a secondary outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Weight Change From Baseline at 12 Weeks in kg</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of Subjects Achieving at Least a 10% Change in Excess Weight From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percent excess weight loss calculated using the Metropolitan Life Tables (MET). The actual amount of excess weight loss (EWL) was examined through the percent of actual weight change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Subjects With Decrease in HbA1c Values From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12 of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>EndoBarrier Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoBarrier Device and Diet &amp; Lifestyle Counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diet &amp; Lifestyle Counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoBarrier Device</intervention_name>
    <description>NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks</description>
    <arm_group_label>EndoBarrier Device</arm_group_label>
    <other_name>EndoBarrier Gastrointestinal Liner</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet &amp; Lifestyle Counseling</intervention_name>
    <description>NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp</description>
    <arm_group_label>EndoBarrier Device</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and &lt; 55 years - Male or Female

          -  BMI &gt; 35 with significant comorbidities (i.e. hypertension, or hyperlipidemia, or
             diabetes) or &gt; 40 BMI &lt;60 (with or without a co-morbid condition)

          -  History of failure with nonsurgical weight loss methods

          -  Candidates for Roux-en-Y gastric bypass

          -  Patients willing to comply with study requirements

          -  Patients who have signed an informed consent form

        Exclusion Criteria:

          -  Patients requiring prescription anticoagulation therapy

          -  Patients with iron deficiency and iron deficiency anemia

          -  Inflammatory bowel disease or condition of the gastrointestinal tract, such as ulcers
             or Crohn's disease

          -  Treatment represents an unreasonable risk to the patient

          -  Pancreatitis or other serious organic conditions

          -  Symptomatic coronary artery disease or pulmonary dysfunction

          -  Patients with known gallstones prior to implant

          -  Known infection at the time of implant

          -  Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or
             gastric varices, congenital or acquired intestinal telangiectasia

          -  Congenital or acquired anomalies of the GI tract such as atresias or stenoses

          -  Pregnant or has the intention of becoming pregnant in the next 12 months

          -  Unresolved alcohol or drug addiction

          -  HIV Positive patients

          -  Patients with hepatitis B or C

          -  Mentally retarded or emotionally unstable, or exhibits psychological characteristics
             which, in the opinion of the investigator, makes the subject a poor candidate for
             device placement or clinical trial

          -  Previous GI surgery that could affect the ability to place the sleeve or the function
             of the implant.

          -  Patients unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during
             the implant period

          -  H. pylori positive patients (Note: patients may be enrolled if they had a prior
             history and were successfully treated)

          -  Patients receiving weight loss medications such as Meridia and Xenical

          -  Family or patient history of a known diagnosis or pre-existing symptoms of systemic
             lupus erythematosus, scleroderma or other autoimmune connective tissue disorder

          -  Patients with gastroesophageal reflux disease (GERD)

          -  Patients with a history of kidney stones

          -  Participating in another ongoing investigational clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Willem Greve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <disposition_first_submitted>April 6, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>GI Dynamics</investigator_affiliation>
    <investigator_full_name>Jan Willem Greve</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EndoBarrier Device</title>
          <description>EndoBarrier + Diet + Lifestyle counseling 12 Week implant duration
EndoBarrier: Monthly visits</description>
        </group>
        <group group_id="P2">
          <title>Control (Diet &amp; Lifestyle Counseling)</title>
          <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Device</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 12 Week Follow up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 16 Week Follow up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24 Week Follow up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unsuccessful procedure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>EndoBarrier subjects with a successful implant</population>
      <group_list>
        <group group_id="B1">
          <title>EndoBarrier and Diet/Lifestyle Counseling</title>
          <description>EndoBarrier + Diet + Lifestyle counseling
EndoBarrier: Monthly visits</description>
        </group>
        <group group_id="B2">
          <title>Control: (Diet and Lifestyle Counseling)</title>
          <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="9.33"/>
                    <measurement group_id="B2" value="41.2" spread="10.46"/>
                    <measurement group_id="B3" value="41.0" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Weight Change From Baseline at 12 Weeks in kg</title>
        <time_frame>12 weeks</time_frame>
        <population>26 subjects received the device. 2 subjects had the device removed before 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>EndoBarrier/Diet and Lifestyle Counseling/12 Weeks</title>
            <description>12 week implantation period</description>
          </group>
          <group group_id="O2">
            <title>Control (Diet &amp; Lifestyle Counseling)</title>
            <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
          </group>
        </group_list>
        <measure>
          <title>Total Weight Change From Baseline at 12 Weeks in kg</title>
          <population>26 subjects received the device. 2 subjects had the device removed before 12 weeks.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="5.83"/>
                    <measurement group_id="O2" value="-5.5" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Subjects Achieving at Least a 10% Change in Excess Weight From Baseline to 12 Weeks</title>
        <description>The percent excess weight loss calculated using the Metropolitan Life Tables (MET). The actual amount of excess weight loss (EWL) was examined through the percent of actual weight change from baseline.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EndoBarrier and Diet and Lifestyle Counseling</title>
            <description>EndoBarrier + Diet + Lifestyle counseling
EndoBarrier: Monthly visits</description>
          </group>
          <group group_id="O2">
            <title>Control (Diet &amp; Lifestyle Counseling)</title>
            <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
          </group>
        </group_list>
        <measure>
          <title>% of Subjects Achieving at Least a 10% Change in Excess Weight From Baseline to 12 Weeks</title>
          <description>The percent excess weight loss calculated using the Metropolitan Life Tables (MET). The actual amount of excess weight loss (EWL) was examined through the percent of actual weight change from baseline.</description>
          <units>% participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8"/>
                    <measurement group_id="O2" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Subjects With Decrease in HbA1c Values From Baseline to Week 12</title>
        <time_frame>Baseline to Week 12 of treatment</time_frame>
        <population>Type 2 Diabetes Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>EndoBarrier/Diet and Lifestyle Counseling/12 Weeks</title>
            <description>12 week implantation period</description>
          </group>
          <group group_id="O2">
            <title>Control (Diet &amp; Lifestyle Counseling)</title>
            <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Subjects With Decrease in HbA1c Values From Baseline to Week 12</title>
          <population>Type 2 Diabetes Subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EndoBarrier and Diet and Lifestyle Counseling</title>
          <description>EndoBarrier + Diet + Lifestyle counseling
EndoBarrier: Monthly visits</description>
        </group>
        <group group_id="E2">
          <title>Control (Diet &amp; Lifestyle Counseling)</title>
          <description>Diet + Lifestyle counseling
Diet + Lifestyle Counseling: Monthly Visits</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Implant site inflammation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra (10.0)">Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager of Clinical Affairs</name_or_title>
      <organization>GI Dynamics, Inc.</organization>
      <phone>781.357.3263</phone>
      <email>kwoessner@gidynamics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

